linjc16/ctgov huggingface dataset:
Efficacy of Nebulized Lidocaine, Salbutamol, and Beclomethasone Plus Salbutamol in the Covid-19 Patients With ARDS on Non-invasive Ventilation; Randomized Control Trial

Study Overview
=================
Brief Summary
-----------------
The COVID-19, a pandemic as declare by WHO1, has a devastating impact on health and economic worldwide2. Literature suggests that acute respiratory distress syndrome (ARDS) develops over 20% of the infected individuals with Coivd-pneumonia3 along with other symptoms like fever followed by cough and dyspnea as well as chest pain in severe cases4. The current preventative strategies are non-specific10, and current interventions are predominantly supportive1. Recently, some studies have demonstrated anti-inflammatory actions for local anesthetics including lidocaine.

Official Title
-----------------
Efficacy of Nebulized Lidocaine, Salbutamol, and Beclomethasone Plus Salbutamol in the Covid-19 Patients With ARDS on Non-invasive Ventilation; Randomized Control Trial

Conditions
-----------------
COVID-19 Acute Respiratory Distress Syndrome

Intervention / Treatment
-----------------
* Drug: Lidocaine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Covid-19 positive Moderate to severe ARDS Exclusion Criteria: patients with COPD or taking bronchodilators and steroids for chronic respiratory illnesses

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Lidocaine group<br> | Drug: Lidocaine<br>* Lidocaine will be used for nebulization of the covid-19 patients and will be compared with other two drugs<br>|
| Placebo Comparator: Salbutamol group<br> | Drug: Lidocaine<br>* Lidocaine will be used for nebulization of the covid-19 patients and will be compared with other two drugs<br>|
| Active Comparator: Beclomethasone plus salbutamol<br> | Drug: Lidocaine<br>* Lidocaine will be used for nebulization of the covid-19 patients and will be compared with other two drugs<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cough suppression | it will be assessed by using cough severity score | within five minutes of initiation of treatment it will be assessed | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| correction of hypoxia | it will be assessed by PaO2 | immediately before and after intervention |
Norepinephrine as Early Vasopressor Therapy in Children Undergoing Mechanical Ventilation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the effectiveness from early infusion of norepinephrine in pediatric patients submitted to mechanical ventilation for the use of sedative and analgesics drugs.

Official Title
-----------------
Norepinephrine as Early Vasopressor Therapy in Children Undergoing Mechanical Ventilation

Conditions
-----------------
Shock, Mechanical Ventilation

Intervention / Treatment
-----------------
* Drug: Norepinephrine
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children, who, in the arrival or during the admission in pediatric intensive care unit, develop the need for mechanical ventilation and continuous infusion of sedatives and/or analgesics Exclusion Criteria: Patients after cardiac arrest Patients with tracheostomy Patients with renal and/or hepatic failure Patients with previous episode of cardiac arrythmia Patients with mechanical ventilation forecast lesser that four days

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Norepinephrine<br> | Drug: Norepinephrine<br>* Solution administration contend titrated norepinephrine in doses of 0,1 to 0,4 mc/kg/min. Initiated solution 24 hours after beginning mechanical ventilation. Use of the solution during 72 hours.<br>|
| Placebo Comparator: Placebo<br> | Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To compare norepinephrine and placebo as initial therapy in pediatric patients submitted to the mechanical ventilation with reference to hemodynamic parameters, diuresis and diuretics' use. |  | 5 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess possible side effects related with the early norepinephrine infusion. |  | 5 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Shock, Respiration, artificial, Norepinephrine
Motivational Program for Smokers Enrolled in a Methadone Maintenance Program

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Stop-smoking programs may help patients stop smoking and prevent cancer from forming. PURPOSE: This clinical trial is studying how well a motivational program works in helping smokers enrolled in a methadone maintenance program quit smoking.

Detailed Description
-----------------
OBJECTIVES: Determine the efficacy of a brief motivational intervention on smoking cessation in smokers enrolled in a methadone maintenance program. OUTLINE: Patients are assigned to 1 of 2 groups. Group 1: Patients undergo assessment at baseline and at 1, 3, and 6 months. Group 2: Patients receive a brief motivational intervention at the time of their baseline assessment and undergo assessment as in group 1. All patients will be offered a 2- to 3-month supply of nicotine patches. PROJECTED ACCRUAL: A total of 400 patients will be accrued for this study.

Official Title
-----------------
Smoking Cessation Among Methadone Maintained Patients

Conditions
-----------------
Unspecified Adult Solid Tumor, Protocol Specific

Intervention / Treatment
-----------------
* Behavioral: smoking cessation intervention
* Other: educational intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Must be currently enrolled in a methadone maintenance program Smokes at least 10 cigarettes a day PATIENT CHARACTERISTICS: Not pregnant No concurrent medical condition that precludes the use of nicotine patches PRIOR CONCURRENT THERAPY: No concurrent use of other nicotine replacement therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: smoking cessation intervention|nan|
|Other: educational intervention|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Nicotine Abstinence |  | 6-months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
unspecified adult solid tumor, protocol specific
Incurable Ill Patients Attitudes Towards Euthanasia and Assisted Suicide

Study Overview
=================
Brief Summary
-----------------
Euthanasia and assisted dying are of growing interest for patients with incurable diseases. The possible methods are widely discussed by patient-societies, physicians, lawyers, theologians and philosophers. During the last years several opinion-polls were conducted with healthy people or medical stuff, but no surveys were conducted to get the attitude of incurable ill patients. The hypothesis of the investigators' study is: Palliative Care Medicine is a better option for incurable ill patients than an assisted suicide.

Official Title
-----------------
Incurable Ill Patients Attitudes to Euthanasia and Assisted Suicide: A Prospective, Multi-Centre Trial in Palliative Care Units in Saxony

Conditions
-----------------
Incurable Cancer Diseases, Other Incurable Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age >= 18 years Incurable illness Mental state thet allows to answer a questionnaire Exclusion Criteria: Somnolence Low mental state Curable disease Depression with danger of acute suicide

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Patients receiving palliative care due to incurable illness | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patients intention to assisted suicide |  | up to four weeks after beginning of palliative treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Euthanasia, Assisted Suicide, Assisted Dying, Palliative Care Medicine
Effect of Healing on Rheumatoid Arthritis

Study Overview
=================
Brief Summary
-----------------
The hypothesis is that healing may influence the patient's general status by altering psychological as well as other body functions of importance for the rheumatoid arthritis. This is tested in a three group design with a control group and two groups receiving healing with or without a healer present. The study is randomized and double blind.

Detailed Description
-----------------
The central claim of healers is that this process facilitates self-healing in the patient. Spiritual healing includes several categories, including 'therapeutic touch' and 'intercessory prayer', and the healing may be attributed to God, spirits, universal forces or energies, biological healing energies residing in the healer, or self-healing powers or energies thought to reside latent in the healed organism. The highly controversial hypothesized effects of distant or spiritual healing contradict our traditional sense of reality and are in conflict with what is generally viewed as being in correspondence with modern science.

Official Title
-----------------
Effect of Healing on Rheumatoid Arthritis: a Three-arm Double-blind, Randomized, Controlled Trial

Conditions
-----------------
Rheumatoid Arthritis

Intervention / Treatment
-----------------
* Other: Healing
* Other: Sham healing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with rheumatoid arthritis in a stable medication the past 3 months written informed consent Exclusion Criteria: Not able to arrange own transport, language problems

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Healing<br>patients receive healing while blindfolded and with hearing protector. The healer is behind a screen and not allowed to speak with the subject. | Other: Healing<br>* Healing in our study is given be a healer no-touch, who just has to be present in the room.<br>* Other names: active healing;|
| Sham Comparator: Sham healing<br>Same design of room as with the healing, while in this case a student is behind the screen | Other: Sham healing<br>* Sham Healing in our study is given be a student no-touch, who just has to be present in the room.<br>* Other names: placebo healing;|
| No Intervention: Control<br>Business as usual in the third arm | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| DAS28 |  | 8 weeks follow-up | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Colour Doppler fraction |  | 8 weeks follow-up |
NOW Thai HAART Study

Study Overview
=================
Brief Summary
-----------------
After Initiation of HAART in peoples who living with HIV/AIDS in Thailand by the year 2000, rapidly expanded HAART access of national project has been promoted in 2004. Free ARVs (For CD4<200cell/cu.mm. or in symptomatic HIV with CD4<250 cell/cu.mm. )and CD4 monitoring has been available. The first-line regimen is d4T+3TC+NVP in mainly the first time (Naive) patients. CD4 response ), rate of opportunistic infection, and neurological outcomes were measured. Rate of ARV change, adverse events,treatment failure, TB co-infection rate, percent changing to EFV-based regimen or PI-based regimen were recorded. Any Adverse Events including, Sever rash, Severe Hepatitis, Lipid abnormalities, Severe Anemia and Other, common AEs will be analysed.

Official Title
-----------------
Neurological Outcomes With in THAI National HAART Program.

Conditions
-----------------
HIV, AIDS, Neurological Complications

Intervention / Treatment
-----------------
* Drug: Highly Active Antiretroviral Treatment (combination of :NRTI, NNRTI,or PI)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: HIV/AIDS patients. Age >15 years. informed consent Exclusion Criteria: Not informed consent

Ages Eligible for Study
-----------------
Minimum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Highly Active Antiretroviral Treatment (combination of :NRTI, NNRTI,or PI)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV, AIDS, Neurological complications, HAART
Intrathecal Bupivacaine Versus Bupivacaine and Clonidine in Paediatrics Age Group:A Comparative Evaluation

Study Overview
=================
Brief Summary
-----------------
The investigators can summarize intrathecal clonidine can potentiate bupivacaine thereby bringing about better quality and longer duration of analgesia, better sedation and better postoperative outcomes with minimal side effects.

Detailed Description
-----------------
In our Randomized controlled, double blind study involving 30 subjects in two groups; the investigators compared the safety, efficacy and quality of using intrathecal hyperbaric bupivacaine 0.5% and hyperbaric bupivacaine 0.5% with clonidine 1µg/kg in paediatric patients undergoing surgeries below T8 dermatome. American Society of Anesthesiologists (ASA) Grade I patients aged between 3-10 years were scheduled for the surgeries below T8 dermatome up to two hrs duration. The patients were randomly allocated in - Group A-who received 0.5%of hyperbaric Bupivacaine 0.4mg/kg for 5 to15 kg or 0.3 mg/kg for more than 15 kg intrathecally. Group B-who received 0.5%of hyperbaric Bupivacaine 0.4mg/kg for 5 to15 kg or 0.3 mg/kg for more than 15 kg and 1µg/kg preservative free clonidine intrathecally. The patients studied across the group did not vary much with respect to age, weight and sex distribution.

Official Title
-----------------
Intrathecal Bupivacaine Versus Bupivacaine and Clonidine in Paediatrics Age Group:A Comparative Evaluation

Conditions
-----------------
Pediatric Spinal Anesthesia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA grade-1 physical status. weight 5-35kg age-3 to 10 yrs Exclusion Criteria: patients with known sensitivity to drugs to be used. gross spinal deformity patients in whom regional anesthesia is contraindicated. patients with peripheral neuropathy. patient with hemodynamic instability.

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 10 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| group-A and group-B<br>Group-A (0.5% hyperbaric bupivacaine 0.4 mg/kg for 5-15 kg or 0.3mg/kg for >15kg) and Group-B (0.5% hyperbaric bupivacaine 0.4 mg/kg for 5-15 kg or 0.3mg/kg for >15 with 1 mcg/kg preservative free clonidine). | |
| group-A and group--B<br>Group-A (0.5% hyperbaric bupivacaine 0.4 mg/kg for 5-15 kg or 0.3mg/kg for >15kg) and Group-B (0.5% hyperbaric bupivacaine 0.4 mg/kg for 5-15 kg or 0.3mg/kg for >15 with 1 mcg/kg preservative free clonidine). | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
bupivacaine, clonidine, pediatric spinal, efficacy, duration, quality, side effects, intrathecal bupivacaine alone, bupivacaine plus clonidine
Identifying Genes That May Increase the Risk for Heart Disease in African Americans

Study Overview
=================
Brief Summary
-----------------
Heart disease and stroke disproportionately affect African Americans in the United States. These conditions are likely caused by both environmental and genetic factors. This study will attempt to identify specific genes of African and European ancestral origins that may influence the development of heart disease in African Americans.

Detailed Description
-----------------
African Americans have a high risk of developing heart disease and stroke, and are more likely to die from heart-related illnesses than other racial and ethnic groups. A large majority of African Americans are descendants of both African and European ancestors who mixed five to six generations ago. Because only a few generations have passed since that time, it is still possible to identify specific genes, the basic units of heredity, as being either African or European in origin. This is a sub study of the Jackson Heart Study, which is examining the environmental and genetic factors that influence the development of heart disease in African Americans. In this study, researchers will examine genes from participants in the Jackson Heart Study to identify specific African and European genes that influence the development of heart disease in African American men and women. This study will use genetic samples from individuals participating in the Jackson Heart Study. There will be no study visits for participants. Study researchers will examine the genetic samples and identify specific African and European genes that may influence the development of heart disease, high blood pressure, lipid disorders, left ventricular hypertrophy, and low birth weight.

Official Title
-----------------
Health Disparities and CVD: Admixture Mapping in the Jackson Heart Study

Conditions
-----------------
Heart Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Unrelated African Americans living in Hinds, Rankin, or Madison County, Mississippi enrolled in the Jackson Heart Study

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 95 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Stroke, Blood Pressure, High, Hypertension, Diabetes Mellitus, Obesity, Cerebrovascular Accident, Atherosclerosis
Changes in Cerebrovascular Reactivity During Cognitive Activation After Cardiopulmonary Bypass: Relation With Intraoperative Embolic Load and Postoperative Neuropsychological Dysfunctions

Study Overview
=================
Brief Summary
-----------------
The study aims to evaluate neuropsychological disorders in CABG patients. Measurements are performed 1 day before, 6 days, 6 months and 3-5 years after the surgery. The relation with cerebrovascular reactivity and embolic load (measured by transcranial Doppler Ultrasonography) is evaluated. Two surgery techniques (on- and off-pump CABG) are compared.

Official Title
-----------------
Changes in Cerebrovascular Reactivity During Cognitive Activation After Cardiopulmonary Bypass: Relation With Intraoperative Embolic Load and Postoperative Neuropsychological Dysfunctions

Conditions
-----------------
CABG-Patients

Intervention / Treatment
-----------------
* Procedure: Determination of neuropsychological status


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: CABG-patients (not urgent) < 70 years old Righthanded Exclusion Criteria: Neurological or psychiatric disease Psychoactive medication Valve operation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 69 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Determination of neuropsychological status|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neuropsychological status |  | after 6 days, 6 months and 3-5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Relation with intra-operative embolic load |  |  |